DaVita (DVA) Stock Forecast & Price Target

$164.19

-1.00 (-0.61%)

(As of 09/17/2024 ET)

DaVita - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 5 Analyst Ratings

Based on 5 Wall Street analysts who have issued ratings for DaVita in the last 12 months, the stock has a consensus rating of "Hold." Out of the 5 analysts, 1 has given a sell rating, 3 have given a hold rating, and 1 has given a buy rating for DVA.

Consensus Price Target

$157.00
-4.38% Downside

High Forecast	$175.00
Average Forecast	$157.00
Low Forecast	$145.00

According to the 5 analysts' twelve-month price targets for DaVita, the average price target is $157.00. The highest price target for DVA is $175.00, while the lowest price target for DVA is $145.00. The average price target represents a forecasted downside of -4.38% from the current price of $164.19.

Type	Current Forecast 9/18/23 to 9/17/24	1 Month Ago 8/19/23 to 8/18/24	3 Months Ago 6/20/23 to 6/19/24	1 Year Ago 9/18/22 to 9/18/23
Consensus Rating	Hold	Hold	Hold	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)	2 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)	4 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$157.00	$154.00	$144.67	$105.29
Forecasted Upside	-4.38% Downside	12.42% Upside	9.67% Upside	15.16% Upside

Central Bank Abandons USD (Ad)

Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold.

Click here now to get your free 'Protect Your Wealth' Guide.

DVA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DVA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

DaVita Stock vs. The Competition

Type	DaVita	Medical Companies	S&P 500
Consensus Rating Score	2.00	2.77	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	-3.90% Downside	985.39% Upside	7.41% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
8/20/2024	Truist Financial 1 of 5 stars	Boost Target	Hold ➝ Hold	$150.00 ➝ $165.00	+9.97%
8/8/2024	UBS Group 4 of 5 stars	Boost Target	Buy ➝ Buy	$169.00 ➝ $175.00	+27.88%
8/7/2024	Bank of America 4 of 5 stars	Boost Target	Underperform ➝ Underperform	$139.00 ➝ $145.00	+9.55%
7/24/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Hold ➝ Hold	$139.00 ➝ $150.00	+5.31%
5/6/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$133.00 ➝ $150.00	+10.03%
5/15/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target		$88.00 ➝ $100.00	+6.70%
My big AI project… (Ad) On Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016. Just click here to register.
5/9/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target		$85.00 ➝ $113.00	+10.50%
2/23/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform	$76.00 ➝ $90.00	+5.42%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:40 PM ET.

DVA Forecast - Frequently Asked Questions

What is DaVita's forecast for 2024?: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for DaVita is $157.00, with a high forecast of $175.00 and a low forecast of $145.00.
Should I buy or sell DaVita stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DaVita in the last twelve months. There is currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" DVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DVA, but not buy additional shares or sell existing shares.
Does DaVita's stock price have much upside?: According to analysts, DaVita's stock has a predicted upside of 12.46% based on their 12-month stock forecasts.
What analysts cover DaVita?: DaVita has been rated by research analysts at Bank of America, TD Cowen, Truist Financial, and UBS Group in the past 90 days.
Do Wall Street analysts like DaVita more than its competitors?: Analysts like DaVita less than other "medical" companies. The consensus rating for DaVita is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how DVA compares to other companies.